Unicycive Therapeutics Stock Analysis

Unicycive Stock Analysis Notes

About 60.0% of the company outstanding shares are owned by institutional investors. The book value of Unicycive Therapeutics was at this time reported as 0.28. The company recorded a loss per share of 0.46. Unicycive Therapeutics had not issued any dividends in recent years. Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. The company was incorporated in 2016 and is based in Los Altos, California. Unicycive Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. For more information please call the company at 650 351 4495 or visit https://unicycive.com.

Unicycive Therapeutics Investment Alerts

Unicycive Therapeutics Upcoming and Recent Events

Unicycive Largest EPS Surprises

View All Earnings Estimates

Unicycive Stock Institutional Investors

Note, although Unicycive Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Unicycive Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 56.26 M.

Unicycive Profitablity

Management Efficiency

Unicycive Therapeutics has return on total asset (ROA) of (0.6285) % which means that it has lost $0.6285 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4705) %, meaning that it created substantial loss on money invested by shareholders. Unicycive Therapeutics' management efficiency ratios could be used to measure how well Unicycive Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 6.42 in 2025, whereas Return On Tangible Assets are likely to drop (2.03) in 2025. At this time, Unicycive Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 16.2 M in 2025, whereas Non Currrent Assets Other are likely to drop (164.4 K) in 2025.

Technical Drivers

As of the 26th of February, Unicycive Therapeutics has the Semi Deviation of 4.38, risk adjusted performance of 0.0607, and Coefficient Of Variation of 1410.85. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Unicycive Therapeutics, as well as the relationship between them.

Unicycive Therapeutics Price Movement Analysis

Unicycive Therapeutics Insider Trading Activities

Unicycive Therapeutics Outstanding Bonds

Unicycive Therapeutics Predictive Daily Indicators

Unicycive Therapeutics Forecast Models

Unicycive Therapeutics' time-series forecasting models are one of many Unicycive Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Unicycive Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Unicycive Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Unicycive shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Unicycive Therapeutics. By using and applying Unicycive Stock analysis, traders can create a robust methodology for identifying Unicycive entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Unicycive analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Unicycive analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Unicycive Therapeutics stock analysis indicators help investors evaluate how Unicycive Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Unicycive Therapeutics shares will generate the highest return on investment. By understating and applying Unicycive Therapeutics stock analysis, traders can identify Unicycive Therapeutics position entry and exit signals to maximize returns.

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.